Search
icatibant (Firazyr)
Indications:
- symptomatic treatment of acute attacks of hereditary angioedema (FDA-approved Aug 2011)
- useful for treatment of ACE-inhibitor induced angioedema [3]
- median time to resolution = 8 hours
Dosage:
- prefilled syringe, 3 mL (30 mg), SQ, preferably abdomen
- a 2nd injection may be given 6 hours after the 1st
- maximum: 3 injections/day
Mechanism of action:
- specific antagonist of bradykinin B2 receptors
General
receptor antagonist
anti-inflammatory agent
References
- Wikipedia: Icatibant
http://en.wikipedia.org/wiki/Icatibant
- Walker EP
FDA Approves Icatibant for Rare Swelling Condition
http://www.medpagetoday.com/ProductAlert/Prescriptions/28193
- Bas M et al
A Randomized Trial of Icatibant in ACE-Inhibitor-Induced Angioedema.
N Engl J Med 2015; 372:418-425. January 29, 2015
PMID: 25629740
http://www.nejm.org/doi/full/10.1056/NEJMoa1312524
- icatibant
http://www.drugs.com/mtm/icatibant.html
- Package Insert
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000899/WC500022966.pdf